Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL Post author: Post published:April 20, 2026 Post category: Continue ReadingConsolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells Post author: Post published:April 20, 2026 Post category: Continue ReadingFecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells
Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Young Adults Post author: Post published:April 20, 2026 Post category: Continue ReadingStem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Young Adults
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel Post author: Post published:April 20, 2026 Post category: Continue ReadingExpanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas Post author: Post published:April 20, 2026 Post category: Continue ReadingAutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma Post author: Post published:April 20, 2026 Post category: Continue ReadingA Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies Post author: Post published:April 20, 2026 Post category: Continue ReadingA Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex) Post author: Post published:April 20, 2026 Post category: Continue ReadingA Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma Post author: Post published:April 20, 2026 Post category: Continue ReadingCD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies Post author: Post published:April 20, 2026 Post category: Continue ReadingA Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
